{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T08:01:14Z","timestamp":1793174474738,"version":"4.5.0"},"reference-count":52,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,20]],"date-time":"2025-03-20T00:00:00Z","timestamp":1742428800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Toxicology Reports"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.toxrep.2025.102008","type":"journal-article","created":{"date-parts":[[2025,3,27]],"date-time":"2025-03-27T05:11:39Z","timestamp":1743052299000},"page":"102008","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Risk-based in silico mutagenic assessment of benzodiazepine impurities using three QSAR tools"],"prefix":"10.1016","volume":"14","author":[{"given":"Srinivas","family":"Birudukota","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhaskar","family":"Mangalapu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramesha Andagar","family":"Ramakrishna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Swagata","family":"Halder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.toxrep.2025.102008_bib1","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.tips.2018.03.006","article-title":"Benzodiazepine binding sites of GABAA receptors","volume":"39","author":"Sigel","year":"2018","journal-title":"Trends Pharm. Sci."},{"issue":"3","key":"10.1016\/j.toxrep.2025.102008_bib2","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.scijus.2017.12.004","article-title":"A quantitative structure-activity relationship (QSAR) model was used to predict GABA-A receptor binding of newly emerging benzodiazepines","volume":"58","author":"Waters","year":"2018","journal-title":"Sci. Justice"},{"key":"10.1016\/j.toxrep.2025.102008_bib3","author":"Allen","year":"2024","journal-title":"GABA Recept."},{"key":"10.1016\/j.toxrep.2025.102008_bib4","author":"Jewett","year":"2024","journal-title":"Physiol., GABA"},{"key":"10.1016\/j.toxrep.2025.102008_bib5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jpba.2019.01.028","article-title":"Analysis of unstable degradation impurities of a benzodiazepine and their quantification without isolation using multiple linear regression","volume":"167","author":"Campbell","year":"2019","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.toxrep.2025.102008_bib6","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.watres.2017.04.063","article-title":"Reaction of diazepam and related benzodiazepines with chlorine. Kinetics, transformation products and in-silico toxicological assessment","volume":"120","author":"Carpinteiro","year":"2017","journal-title":"Water Res."},{"key":"10.1016\/j.toxrep.2025.102008_bib7","series-title":"M7 Assessment and Control of DNA Reactive (Mutagenic) Impurities in Pharmaceuticals to Limit Potential Carcinogenic Risk-Scientific Guideline","author":"ICH","year":"2017"},{"key":"10.1016\/j.toxrep.2025.102008_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.yrtph.2019.104488","article-title":"Transitioning to composite bacterial mutagenicity models in ICH M7 (Q) SAR analyses","volume":"109","author":"Landry","year":"2019","journal-title":"Regul. Toxicol. Pharmacol."},{"key":"10.1016\/j.toxrep.2025.102008_bib9","series-title":"Silico Methods for Predicting Drug Toxicity","first-page":"537","article-title":"Use of In Silico Methods for Regulatory Toxicological Assessment of Pharmaceutical Impurities","author":"Kovarich","year":"2022"},{"issue":"1","key":"10.1016\/j.toxrep.2025.102008_bib10","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s41021-021-00206-1","article-title":"Bacterial mutagenicity test data: collection by the task force of the Japan pharmaceutical manufacturers association","volume":"43","author":"Hakura","year":"2021","journal-title":"Genes Environ."},{"issue":"4","key":"10.1016\/j.toxrep.2025.102008_bib11","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1177\/0261192920965977","article-title":"A review of in silico tools as alternatives to animal testing: principles, resources and applications","volume":"48","author":"Madden","year":"2020","journal-title":"Altern. Lab. Anim."},{"key":"10.1016\/j.toxrep.2025.102008_bib12","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/s00204-008-0279-9","article-title":"Alternative methods to safety studies in experimental animals: role in the risk assessment of chemicals under the new European Chemicals Legislation (REACH)","volume":"82","author":"Lilienblum","year":"2008","journal-title":"Arch. Toxicol."},{"key":"10.1016\/j.toxrep.2025.102008_bib13","doi-asserted-by":"crossref","first-page":"668","DOI":"10.3389\/fphys.2017.00668","article-title":"Human in silico drug trials demonstrate higher accuracy than animal models in predicting clinical pro-arrhythmic cardiotoxicity","volume":"8","author":"Passini","year":"2017","journal-title":"Front. Physiol."},{"key":"10.1016\/j.toxrep.2025.102008_bib14","unstructured":"U.S. Food and Drug Administration: Center for Drug Evaluation and Research. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH). M7 (2023): Assessment and Control of DNA Reactive (Mutagenic) Impurities in Pharmaceuticals to Limit Potential Carcinogenic Risk. Geneva; 2023 Jul \u3008https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/guidance-industry-m7r2-assessment-and-control-dna-reactive-mutagenic-impurities-pharmaceuticals\u3009."},{"issue":"12","key":"10.1016\/j.toxrep.2025.102008_bib15","doi-asserted-by":"crossref","first-page":"9894","DOI":"10.3390\/ijms24129894","article-title":"The VEGA Tool to check the applicability domain gives greater confidence in the prediction of in silico models","volume":"24","author":"Danieli","year":"2023","journal-title":"Int J. Mol. Sci."},{"issue":"3","key":"10.1016\/j.toxrep.2025.102008_bib16","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1080\/10590501.2014.938955","article-title":"Evaluation of QSAR models for the prediction of Ames genotoxicity: a retrospective exercise on the chemical substances registered under the EU REACH regulation","volume":"32","author":"Cassano","year":"2014","journal-title":"J. Environ. Sci. Health, Part C."},{"issue":"4","key":"10.1016\/j.toxrep.2025.102008_bib17","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1021\/cr100222q","article-title":"Mechanisms of chemical carcinogenicity and mutagenicity: a review with implications for predictive toxicology","volume":"111","author":"Benigni","year":"2011","journal-title":"Chem. Rev."},{"issue":"2","key":"10.1016\/j.toxrep.2025.102008_bib18","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.yrtph.2013.08.008","article-title":"Validation of Toxtree and SciQSAR in silico predictive software using a publicly available benchmark mutagenicity database and their applicability for the qualification of impurities in pharmaceuticals","volume":"67","author":"Contrera","year":"2013","journal-title":"Regul. Toxicol. Pharmacol."},{"issue":"16","key":"10.1016\/j.toxrep.2025.102008_bib19","doi-asserted-by":"crossref","first-page":"4432","DOI":"10.1039\/C6GC00720A","article-title":"Assessment of predictive models for estimating the acute aquatic toxicity of organic chemicals","volume":"18","author":"Melnikov","year":"2016","journal-title":"Green. Chem."},{"issue":"5","key":"10.1016\/j.toxrep.2025.102008_bib20","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1007\/s00204-022-03252-y","article-title":"Prediction reliability of QSAR models: an overview of various validation tools","volume":"96","author":"De","year":"2022","journal-title":"Arch. Toxicol."},{"key":"10.1016\/j.toxrep.2025.102008_bib21","unstructured":"OECD. Guidance document on the validation of (Q) SAR models. Paris, France. Organisation for Economic Co-operation and Development. Environmental Health and Safety Publications. Series on Testing and Assessment. No. 69. 2007:154. \u3008http:\/\/www.oecd.org\/officialdocuments\/publicdisplaydocumentpdf\/?doclanguage=en&cote=env\/jm\/mono\u3009(2007)."},{"key":"10.1016\/j.toxrep.2025.102008_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.comtox.2024.100326","article-title":"The OECD (Q)SAR Assessment Framework: A tool for increasing regulatory uptake of computational approaches","volume":"31","author":"Gissi","year":"2024","journal-title":"Comput. Toxicol."},{"key":"10.1016\/j.toxrep.2025.102008_bib23","article-title":"United States Pharmacopoeia and National Formulary (USP 43-NF 38)","volume":"2","author":"USP","year":"2022"},{"key":"10.1016\/j.toxrep.2025.102008_bib24","series-title":"Indian Pharmacopoeia","author":"IPC","year":"2022"},{"key":"10.1016\/j.toxrep.2025.102008_bib25","unstructured":"Council of Europe ED for the Q of M and HC (EDQM); European Pharmacopoeia. 11th ed. Vol. 2. Strasbourg, France: European Pharmacopoeia; 2022. \u3008https:\/\/www.edqm.eu\/en\/european-pharmacopoeia-ph.-eur.-11th-edition\u3009."},{"key":"10.1016\/j.toxrep.2025.102008_bib26","article-title":"Q)SAR assessments of potentially mutagenic impurities: a regulatory perspective on the utility of expert knowledge and data submission","author":"Powley","year":"2014","journal-title":"Regul. Toxicol. Pharmacol."},{"key":"10.1016\/j.toxrep.2025.102008_bib27","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.yrtph.2016.02.004","article-title":"Principles and procedures for implementation of ICH M7 recommended (Q) SAR analyses","volume":"77","author":"Amberg","year":"2016","journal-title":"Regul. Toxicol. Pharmacol."},{"key":"10.1016\/j.toxrep.2025.102008_bib28","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.jpba.2018.01.026","article-title":"Isolation, identification, and characterisation of two novel process-related impurities in olanzapine","volume":"152","author":"Zhuang","year":"2018","journal-title":"J. Pharm. Biomed. Anal."},{"issue":"15","key":"10.1016\/j.toxrep.2025.102008_bib29","doi-asserted-by":"crossref","first-page":"3149","DOI":"10.1039\/c1an15155j","article-title":"Development of a simple and stability-indicating RP-HPLC method for determining olanzapine and related impurities generated in the preparative process","volume":"136","author":"Cui","year":"2011","journal-title":"Analyst"},{"issue":"2","key":"10.1016\/j.toxrep.2025.102008_bib30","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.jpba.2011.05.003","article-title":"Identification of oxidative degradation impurities of Olanzapine drug substance as well as drug product","volume":"56","author":"Rao","year":"2011","journal-title":"J. Pharm. Biomed. Anal."},{"issue":"2","key":"10.1016\/j.toxrep.2025.102008_bib31","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1002\/jps.2600810216","article-title":"Autoxidation of Tetrazepam in Tablets: Prediction of Degradation Impurities from the Oxidative Behavior in Solution","volume":"81","author":"Giovanni","year":"1992","journal-title":"J. Pharm. Sci."},{"issue":"1\u20133","key":"10.1016\/j.toxrep.2025.102008_bib32","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.forsciint.2008.08.012","article-title":"Case report: Etizolam and its major metabolites in two unnatural death cases","volume":"182","author":"Nakamae","year":"2008","journal-title":"Forensic Sci. Int"},{"issue":"3","key":"10.1016\/j.toxrep.2025.102008_bib33","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1093\/jat\/bkac096","article-title":"Etizolam and Its Major Metabolites: A Short Review","volume":"47","author":"Al Bahri","year":"2023","journal-title":"J. Anal. Toxicol."},{"issue":"1","key":"10.1016\/j.toxrep.2025.102008_bib34","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1093\/mutage\/gey031","article-title":"Improvement of quantitative structure\u2013activity relationship (QSAR) tools for predicting Ames mutagenicity: outcomes of the Ames\/QSAR International Challenge Project","volume":"34","author":"Honma","year":"2019","journal-title":"Mutagenesis"},{"key":"10.1016\/j.toxrep.2025.102008_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/j.comtox.2020.100143","article-title":"Criteria for assessing the reliability of toxicity predictions: I. TIMES ames the mutagenicity model","volume":"17","author":"Petkov","year":"2021","journal-title":"Comput. Toxicol."},{"key":"10.1016\/j.toxrep.2025.102008_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.scitotenv.2020.141468","article-title":"Optimisation of a pre-metabolisation procedure using rat liver S9 and cell-extracted S9 in the Ames fluctuation test","volume":"749","author":"Shao","year":"2020","journal-title":"Sci. Total Environ."},{"issue":"2","key":"10.1016\/j.toxrep.2025.102008_bib37","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1093\/mutage\/gev082","article-title":"Utility of metabolic activation mixtures containing human hepatic post-mitochondrial supernatant (S9) for in vitro genetic toxicity assessment","volume":"31","author":"Cox","year":"2016","journal-title":"Mutagenesis"},{"issue":"4","key":"10.1016\/j.toxrep.2025.102008_bib38","doi-asserted-by":"crossref","DOI":"10.1002\/cem.2992","article-title":"Is it possible to improve the quality of predictions from an \"intelligent\" use of multiple QSAR\/QSPR\/QSTR models?","volume":"32","author":"Roy","year":"2018","journal-title":"J. Chemom."},{"key":"10.1016\/j.toxrep.2025.102008_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/j.yrtph.2023.105403","article-title":"Mutagenic impurities in pharmaceuticals: a critical assessment of the cohort of concern with a focus on N-nitrosamines","volume":"141","author":"Snodin","year":"2023","journal-title":"Regul. Toxicol. Pharmacol."},{"issue":"5","key":"10.1016\/j.toxrep.2025.102008_bib40","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1016\/j.xphs.2023.01.028","article-title":"Current threat of nitrosamines in pharmaceuticals and scientific strategies for risk mitigation","volume":"112","author":"Tuesuwan","year":"2023","journal-title":"J. Pharm. Sci."},{"issue":"5","key":"10.1016\/j.toxrep.2025.102008_bib41","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1002\/em.22087","article-title":"Mechanisms of DNA damage, repair, and mutagenesis","volume":"58","author":"Chatterjee","year":"2017","journal-title":"Environ. Mol. Mutagen"},{"issue":"8","key":"10.1016\/j.toxrep.2025.102008_bib42","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1021\/tx200135s","article-title":"Metabolism and biomarkers of heterocyclic aromatic amines in molecular epidemiology studies: lessons learned from aromatic amines","volume":"24","author":"Turesky","year":"2011","journal-title":"Chem. Res Toxicol."},{"issue":"1","key":"10.1016\/j.toxrep.2025.102008_bib43","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s41021-021-00200-7","article-title":"Metabolism and biomarkers of heterocyclic aromatic amines in humans","volume":"43","author":"Bellamri","year":"2021","journal-title":"Genes Environ."},{"issue":"5","key":"10.1016\/j.toxrep.2025.102008_bib44","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1042\/BST20180519","article-title":"Carcinogens and DNA damage","volume":"46","author":"Barnes","year":"2018","journal-title":"Biochem Soc. Trans."},{"issue":"2","key":"10.1016\/j.toxrep.2025.102008_bib45","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.mrgentox.2007.10.022","article-title":"DNA-damaging activity and mutagenicity of 16 newly synthesized thiazolo [5, 4-a] acridine derivatives with high photo-inducible cytotoxicity","volume":"650","author":"Di Giorgio","year":"2008","journal-title":"Mutat. Res. \/Genet. Toxicol. Environ. Mutagen."},{"issue":"2","key":"10.1016\/j.toxrep.2025.102008_bib46","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.mrgentox.2007.05.004","article-title":"Genotoxicity profiles of common alkyl halides and esters with alkylating activity","volume":"633","author":"Sobol","year":"2007","journal-title":"Mutat. Res. \/Genet. Toxicol. Environ. Mutagen."},{"issue":"3","key":"10.1016\/j.toxrep.2025.102008_bib47","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.jpba.2008.06.009","article-title":"Control and analysis of alkyl and benzyl halides and other related reactive organohalides as potential genotoxic impurities in active pharmaceutical ingredients (APIs)","volume":"48","author":"Elder","year":"2008","journal-title":"J. Pharm. Biomed. Anal."},{"issue":"14","key":"10.1016\/j.toxrep.2025.102008_bib48","doi-asserted-by":"crossref","first-page":"4437","DOI":"10.3390\/molecules27144437","article-title":"Analytical method development for 19 alkyl halides as potential genotoxic impurities by analytical quality by design","volume":"27","author":"Lee","year":"2022","journal-title":"Molecules"},{"key":"10.1016\/j.toxrep.2025.102008_bib49","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112327","article-title":"Epoxide containing molecules: a good or a bad drug design approach","volume":"201","author":"Gomes","year":"2020","journal-title":"Eur. J. Med Chem."},{"issue":"9","key":"10.1016\/j.toxrep.2025.102008_bib50","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1093\/carcin\/bgt164","article-title":"Mutagenicity and tumorigenicity of the four enantiopure bay-region 3,4-diol-1,2-epoxide isomers of dibenz[a,h]anthracene","volume":"34","author":"Chang","year":"2013","journal-title":"Carcinogenesis"},{"issue":"5","key":"10.1016\/j.toxrep.2025.102008_bib51","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1021\/acs.chemrestox.6b00018","article-title":"Modeling of toxicity-relevant electrophilic reactivity for guanine with epoxides: estimating the hard and soft acids and bases (HSAB) parameter as a predictor","volume":"29","author":"Zhang","year":"2016","journal-title":"Chem. Res Toxicol."},{"issue":"3","key":"10.1016\/j.toxrep.2025.102008_bib52","first-page":"269","article-title":"A descriptor-based analysis to highlight the mechanistic rationale of mutagenicity","volume":"39","author":"Gadaleta","year":"2021","journal-title":"J. Environ. Sci. Health, Part C."}],"container-title":["Toxicology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221475002500126X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221475002500126X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T14:58:58Z","timestamp":1762613938000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S221475002500126X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":52,"alternative-id":["S221475002500126X"],"URL":"https:\/\/doi.org\/10.1016\/j.toxrep.2025.102008","relation":{},"ISSN":["2214-7500"],"issn-type":[{"value":"2214-7500","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Risk-based in silico mutagenic assessment of benzodiazepine impurities using three QSAR tools","name":"articletitle","label":"Article Title"},{"value":"Toxicology Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.toxrep.2025.102008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"102008"}}